Document is current
Any future updates will be listed below
-
Authors
Shic, Frederick
Naples, Adam J.
Barney, Erin C.
Chang, Shou An
Li, Beibin
McAllister, Takumi
Kim, Minah
Dommer, Kelsey J.
Hasselmo, Simone
Atyabi, Adham
Wang, Quan
Helleman, Gerhard
Levin, April R.
Seow, Helen
Bernier, Raphael
Charwaska, Katarzyna
Dawson, Geraldine
Dziura, James
Faja, Susan
Jeste, Shafali Spurling
Johnson, Scott P.
Murias, Michael
Nelson, Charles A.
Sabatos-DeVito, Maura
Senturk, Damla
Sugar, Catherine A.
Webb, Sara J.
McPartland, James C. https://orcid.org/0000-0002-2570-0746
-
Funding
Funding for this research was provided by:
national institute of mental health (U19 MH108206, K01 MH104739)
- License Information
-
More Information
Article History
Received: 5 July 2021
Accepted: 20 December 2021
First Online: 21 March 2022
Change Date: 18 March 2023
Change Type: Update
Change Details: The presentation of the consortium name has been corrected throughout the article.
Declarations
:
: Informed consent/assent was obtained from all guardians and participants after procedures were fully explained and the opportunity to ask questions offered. The protocol was approved and overseen by a central IRB at Yale University (HIC#: 1509016477; FWA00002571).
: No identifying information of any participant is presented in this manuscript. Stimuli examples which contain likenesses of individuals have been deidentified using black bars over individuals’ eyes.
: The authors AJN, ECB, SAC, BL, TM, MK, KD, SH, AA, QW, GH, ARL, HS, RB, KC, JD, SF, SSJ, SPJ, MM, CAN, MS, DS, CAS, and SJW declare that they have no competing interests. James C. McPartland consults with Customer Value Partners, Bridgebio, Determined Health, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, and Springer. He has stock interests in Modern Clinics. Dr. Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili Interactive, Inc, LabCorp, Inc, Roche Pharmaceutical Company, and Tris Pharma, and is a consultant to Apple, Gerson Lehrman Group, Guidepoint Global, Inc, and is CEO of DASIO, LLC. Dr. Dawson has stock interests in Neuvana, Inc. Frederick Shic consults for Roche Pharmaceutical Company, Janssen Research and Development, BlackThorn Therapeutics, and BioStream Technologies. Sara J. Webb consults for Janssen Research and Development. No company contributed to funding of this study. A representative from Janssen served on the FNIH Biomarkers Consortium Project Team and provided in kind support in terms of sharing experiences and preliminary results of the JAKE study.
